Primary Amyloidosis Clinical Trials

Find Primary Amyloidosis Clinical Trials Near You

Elevated Rate Pacing of Cardiac Amyloidosis

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adults 18 and older

• Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee

• Implanted Cardiac Pacemaker (+/- Defibrillator)

• Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation

• Non-dilated left ventricle by echocardiography

• Ability to provide written consent

• English Speaking

Locations
United States
Minnesota
University of Minnesota
RECRUITING
Minneapolis
Contact Information
Primary
Meghan Muscala
payne324@umn.edu
612-626-5863
Time Frame
Start Date: 2025-10-10
Estimated Completion Date: 2026-10-10
Participants
Target number of participants: 10
Treatments
Experimental: Elevated Pacemaker Rate
CA clinic patients with pacemakers will receive a personalized pacing protocol individual to their height and left ventricular ejection fraction.
Sponsors
Leads: University of Minnesota

This content was sourced from clinicaltrials.gov